NASDAQ:SBOT - Stellar Biotechnologies Stock Price, Price Target & More

Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."

Stellar Biotechnologies's stock reverse split before market open on Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of Stellar Biotechnologies stock prior to the reverse split would have 14 shares after the split.

Stellar Biotechnologies Inc (NASDAQ:SBOT) announced its earnings results on Tuesday, May, 9th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.05) by $0.28. The biotechnology company had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.33 million. Stellar Biotechnologies had a negative return on equity of 77.77% and a negative net margin of 4,766.06%. View Stellar Biotechnologies' Earnings History.

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stellar Biotechnologies in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."

Some companies that are related to Stellar Biotechnologies include Diffusion Pharmaceuticals (DFFN), ESSA Pharma (EPIX), Pulmatrix (PULM), IntelliPharmaCeutics Intl (IPCI), Midatech Pharma (MTP), Egalet (EGLT), Prana Biotechnology (PRAN), Aralez Pharmaceuticals (ARLZ), Innovus Pharmaceuticals (INNV), Agile Therapeutics (AGRX), Kaya (KAYS), MusclePharm (MSLP), Bio-Path (BPTH), Cyclacel Pharmaceuticals (CYCC) and Wellness Center USA (WCUI).

News stories about SBOT stock have trended somewhat negative this week, Accern reports. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Stellar Biotechnologies earned a news impact score of -0.01 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 45.76 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Shares of SBOT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SBOT stock can currently be purchased for approximately $1.76.

Stellar Biotechnologies has a market capitalization of $5.83 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-5,030,000.00 in net income (profit) each year or ($3.43) on an earnings per share basis. Stellar Biotechnologies employs 28 workers across the globe.

Stellar Biotechnologies' mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company can be reached via phone at 805-488-2800 or via email at [email protected]